当前位置: 首页 > 期刊 > 《糖尿病新世界》 > 2018年第19期
编号:13336705
羟苯磺酸钙联合前列地尔辅助治疗糖尿病肾病的临床观察(2)
http://www.100md.com 2018年10月1日 《糖尿病新世界》 2018年第19期
     [2] Tervaert TW.Mooyaart AL.Amann K.et al.Pathologic Classi fication 0f diabetic nephmpathy[J]. Am Soe Nephrol,2010,21(4):556—563.

    [3] Yamagishi S,Fukami K,Ueda S,et a1.Molecular mechanisms of diabetic nephropathy and its therapeutic intervention[J].Curt Drug Targets,2007,8(8):952.

    [4] Zhang X. Therapeutic effects of calcium dobesilate on diabe tic nephropathy mediated through reduction of expression of PAI 1[J]. Experimental and therapeutic medicine, 2013, 5(1): 295-299.

    [5] Gao M J, Liu M, Li B, et al.Protective effect of calcium dobesilate against early diabetic nephropathy of rat kidney[J].Yao xue xue bao=Acta pharmaceutica Sinica, 2009, 44(2): 126-133.

    [6] Xiaocheng L, Xinming L. Effect of calcium dobesilate on nephropathy in type 2 diabetic rats[J]. Journal of Huazhong University of Science and Technology [Medical Sciences], 2005, 25(1): 36-38.

    [7] Itoh Y, Yasui T, Kakizawa H, et al. The therapeutic effect of lipo PGE 1 on diabetic neuropathy-changes in endothelin and various angiopathic factors[J]. Prostaglandins & other lipid mediators, 2001, 66(3): 221-234.

    [8] Miao Y, Zhong Y, Yan H, et al. Alpros tadil plays a protective role in contrast-induced nephropathy in the elderly[J]. Int Urol Nephrol,2013(45):1179-1185.

    (收稿日期:2018-07-02), 百拇医药(刘瑛)
上一页1 2